---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000008"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T15:16:04.574116+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression

## Summary
- SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.
- No statistically significant improvement on any secondary endpoints versus placebo.
- Safety profile consistent with prior trials; few adverse events and well-tolerated.
- CEO Jack Khattar expressed disappointment; will review data with partner Navitor Pharmaceuticals.
- Study enrolled ~250 adults with TRD across 40 U.S. clinical sites.

## SEC filing metadata
- accession: 0001356576-25-000008
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/0001356576-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/supn-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000008
- JSON: https://secwatch.observer/filing/0001356576-25-000008.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.